RecruitingPhase 2NCT05748171
A Study to Learn More About the Study Medicine Called Inotuzumab Ozogamicin (InO) in Children (1 to <18 Years) With First Relapse ALL
Studying Acute lymphoblastic leukemia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Pfizer
- Principal Investigator
- Pfizer CT.gov Call CenterPfizer
- Intervention
- Inotuzumab ozogamicin(drug)
- Enrollment
- 100 enrolled
- Eligibility
- 1-17 years · All sexes
- Timeline
- 2023 – 2036
Study locations (30)
- St. Anna Kinderspital, Vienna, Austria
- Cliniques universitaires Saint-Luc, Brussels, Bruxelles-capitale, Région de, Belgium
- UZ Gent, Ghent, Oost-vlaanderen, Belgium
- UZ Leuven, Leuven, Vlaams-brabant, Belgium
- Detska nemocnice FN Brno, Brno, Brno-město, Czechia
- Fakultni Nemocnice Motol a Homolka, Prague, Czechia
- Rigshospitalet, Copenhagen, Capital Region, Denmark
- Helsinki university hospital, Helsinki, Finland
- Centre Hospitalier Universitaire de Nice - Hôpital l'Archet, Nice, Alpes-maritimes, France
- CHU Strasbourg-Hautepierre, Service d'hematologie oncologie pediatrique, pediatrie 3, Strasbourg, Alsace, France
- Bordeaux University Hospital - Pellegrin, Bordeaux, Aquitaine, France
- CHU de Toulouse - Hôpital des Enfants - Hemato-Immuno-Oncologie, Toulouse, Haute-garonne, France
- Hôpital Arnaud de Villeneuve - CHU Montpellier, Montpellier, Hérault, France
- Centre Hospitalier Régional Universitaire de Nancy - Hôpitaux de Brabois, Vandœuvre-lès-Nancy, Meurthe-et-moselle, France
- Hôpital Jeanne de Flandre - CHRU, Lille, NORD, France
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05748171 on ClinicalTrials.govOther trials for Acute lymphoblastic leukemia
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT05621291A Study to Evaluate Next-Generation Sequencing (NGS) Testing and Monitoring of B-cell Recovery to Guide Management Following Chimeric Antigen Receptor T-cell (CART) Induced Remission in Children and Young Adults With B Lineage Acute Lymphoblastic Leu...National Cancer Institute (NCI)
- RECRUITINGPHASE2NCT07328503CD22 CAR T-cells to Extend Remission Following Commercial CD19 CAR T-cells in Children, Adolescents, and Adults With Relapsed/Refractory B-cell Acute Lymphoblastic LeukemiaNational Cancer Institute (NCI)
- RECRUITINGPHASE2NCT06738368Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (DA-EPOCH) With or Without Rituximab Plus Recombinant Erwinia Asparaginase (JZP458) for the Treatment of Newly Diagnosed Ph Negative B-Acute Lymphoblastic Leukemia or T Acute Lymphoblastic LeukemiaUniversity of Washington
- ENROLLING BY INVITATIONNCT07511959Autologous Exosomes From Platelet-rich Plasma as a Modern Tool of Regenerative DentistryWroclaw Medical University
- RECRUITINGNANCT07191119Transcutaneous Auricular Vagus Nerve Stimulation for Insomnia in Survivors of Childhood Acute Lymphoblastic LeukemiaSt. Jude Children's Research Hospital
- RECRUITINGNANCT07177183Low Serum Creatinine as a Predictor of Prolonged Mechanical Ventilation and Weaning FailureUniversity Hospital Ostrava
- RECRUITINGPHASE2NCT07275762Y-4 to Treat the Postherpetic NeuralgiaNeurodawn Pharmaceutical Co., Ltd.
- RECRUITINGNANCT07201974Virtual Reality for Post-Stroke Gait RehabilitationMcGill University